The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Cognitive Function in a Randomized Trial of Evolocumab
Open accessAbstract
Background Findings from clinical trials of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol that result from their use are associated with cognitive deficits. Methods In a subgroup of patients from a randomized, placebo-controlled trial of evolocumab added to statin therapy, we prospectively assessed cognitive function using the Cambridge Neuropsychological Test Automated Battery. The primary end point was the score on the spatial working memory strategy index of executive function (scores range from 4 to 28, with lower scores indicating a more efficient use of strategy and planning). Secondary end points were the scores for working memory (scores range from 0 to 279, with lower scores indicating fewer errors), episodic memory (scores range from 0 to 70, with lower scores indicating fewer errors), and psychomotor speed (scores range from 100 to 5100 msec, with faster times representing better performance). Assessments of cognitive function were performed at baseline, week 24, yearly, and at the end of the trial. The primary analysis was a noninferiority comparison of the mean change from baseline in the score on the spatial working memory strategy index of executive function between the patients who received evolocumab and those who received placebo; the noninferiority margin was set at 20% of the standard deviation of the score in the placebo group. Results A total of 1204 patients were followed for a median of 19 months; the mean (±SD) change from baseline over time in the raw score for the spatial working memory strategy index of executive function (primary end point) was -0.21±2.62 in the evolocumab group and -0.29±2.81 in the placebo group (P<0.001 for noninferiority; P=0.85 for superiority). There were no significant between-group differences in the secondary end points of scores for working memory (change in raw score, -0.52 in the evolocumab group and -0.93 in the placebo group), episodic memory (change in raw score, -1.53 and -1.53, respectively), or psychomotor speed (change in raw score, 5.2 msec and 0.9 msec, respectively). In an exploratory analysis, there were no associations between LDL cholesterol levels and cognitive changes. Conclusions In a randomized trial involving patients who received either evolocumab or placebo in addition to statin therapy, no significant between-group difference in cognitive function was observed over a median of 19 months. (Funded by Amgen; EBBINGHAUS ClinicalTrials.gov number, NCT02207634 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trials of PCSK9 inhibitors in cardiovascular populations consistently showed substantial reductions in LDL cholesterol without negative cognitive effects [11,22].”
From The Roles of PCSK9 in Alzheimer’s Disease: A Systematic Review of Clinical, Genetic, and Preclinical Evidence (2025) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“an anti-PCSK9 antibody study observed no significant between-group difference in cognitive function over a median of 19 months [66].”
From PCSK9 acts as a key regulator of Aβ clearance across the blood–brain barrier (2022) · cites this paper as [66]
The cited source says what the claim attributes to it.
In the citing paper
“large cardiovascular trials of PCSK9 antibodies such as evolocumab have not demonstrated cognitive harm10,43”
From Small-molecule PCSK9 inhibition enhances BBB amyloid-β clearance and suppresses microglial inflammation in Alzheimer’s disease models (2026) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, no change in cognitive function has been reported in studies with the addition of ezetimibe (119) or PCSK9 inhibitors (121,170) to statin therapy, including among individuals treated to very low LDL cholesterol levels.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [170]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, no change in cognitive function has been reported in studies with the addition of ezetimibe (112) or PCSK9 monoclonal antibodies (115,164) to statin therapy, including among individuals treated to very low LDL cholesterol levels.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“Our findings are in line with data from PCSK9 inhibitor clinical trials (Giugliano et al., 2017; Mannarino et al., 2018; Gencer et al., 2020; Ray et al., 2020) and from observations that people carrying loss-of-function mutations of the PCSK9 gene have no signs of neurological defects (Cohen et al., 2005, 2006; Zhao et al., 2006; Hooper et al., 2007; Mefford et al., 2018).”
From PCSK9 deficiency alters brain lipid composition without affecting brain development and function (2023) · cites this paper as Giugliano et al., 2017
In the citing paper
“The absolute benefit from statin treatment was lower in people in primary prevention, who are typically at lower risk [36,38,214,215].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [215]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Self-citationEzetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citationEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Self-citationEfficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Self-citationPlanning and spatial working memory following frontal lobe lesions in man
Owen, A. M., Downes, J. J., Sahakian, B. J., Polkey, C. E., & Robbins, T. W. (1990) · Neuropsychologia · doi:10.1016/0028-3932(90)90137-d · Cited by 1,284
SAHAKIAN, B. J., MORRIS, R. G., EVENDEN, J. L., HEALD, A., LEVY, R., PHILPOT, M., & ROBBINS, T. W. (1988) · Brain · doi:10.1093/brain/111.3.695 · Cited by 666
The measurement of everyday cognition (ECog): Scale development and psychometric properties.
Farias, S. T., Mungas, D., Reed, B., Cahn, D. A., Jagust, W. J., Baynes, K., & DeCarli, C. S. (2008) · Neuropsychology · doi:10.1037/0894-4105.22.4.531 · Cited by 665
Robbins, T. W., James-Galton, M., Owen, A. M., Sahakian, B. J., Lawrence, A. D., McInnes, L., & Rabbitt, P. (1998) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617798455073 · Cited by 629
Schmermund, A., Möhlenkamp, S., Stang, A., Grönemeyer, D. H. W., Seibel, R. M. M., Hirche, H., Mann, K., Siffert, W., Lauterbach, K. W., Siegrist, J., et al. (2002) · American Heart Journal · doi:10.1067/mhj.2002.123579 · Cited by 582
Research works printed but not linked: 1
- Jessup C. Cambridge Cognition awarded FDA marketing clearance for Cantab mobile. FDA News. January 26, 2017 (http://www.fdanews.com/articles/180219-cambridge-cognition-awarded-fda-marketing-clearance-for-cantab-mobile).
Cited by
Sorted by citations
Items 301–400 of 493
Pharmacological management of cardiovascular risk in chronic inflammatory rheumatic diseases
Panoulas, V. F., & Kitas, G. D. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1766964 · Cited by 7
Quiroga, B., Ramos, P. M., & Chiva, V. Á. (2020) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2020.11.004 · Cited by 6
Bell, A. S., O’Connell, E. M., & Lohoff, F. W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00036-5 · Cited by 7
So low… so far so good: neurocognitive impact of lowering LDL-C levels with PCSK9 inhibitors
Gencer, B., & Mach, F. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx742 · Cited by 6
Self-citationNew and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering
Gaudet, D., Larouche, M., Raal, F. J., & Catapano, A. L. (2026) · Circulation Research · doi:10.1161/circresaha.126.327270 · Cited by 5
Qureshi, Z. A., Khanzada, M., Safi, A., Fatima, E., Altaf, F., & Vittorio, T. J. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001945 · Cited by 5
Reda, A., Shawky, A., Farag, E.-S. M., Mostafa, T. M. N., Farag, N. M., Elbahry, A., Sanad, O., Bendary, A., Elkersh, A., Selim, M., et al. (2020) · The Egyptian Heart Journal · doi:10.1186/s43044-020-00058-0 · Cited by 5
Cequier, A. R., Arrarte, V., Campuzano, R., Castro, A., Cordero, A., Olmo, M. R. F., García–Moll, X., Gómez‐Doblas, J. J., de Sá, E. L., Núñez, J. E., et al. (2020) · REC CardioClinics · doi:10.1016/j.rccl.2020.10.017 · Cited by 5
Ghouse, J., Ahlberg, G., Bundgaard, H., & OLESEN, M. S. (2021) · Diabetes Care · doi:10.2337/dc21-0955 · Cited by 5
Rivera, F. B., Cha, S. W., Magalong, J. V., Bantayan, N. R. B., Cruz, L. L. A., Arias-Aguirre, E., Aguirre, Z., Varona, M. C., Co, E. M. F., Lumbang, G. N. O., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2363971 · Cited by 5
PCSK9 inhibitor effectively alleviated cognitive dysfunction in a type 2 diabetes mellitus rat model
Yang, Y., Wang, Y., Wang, Y., Ke, T., & Zhao, L. (2024) · PeerJ · doi:10.7717/peerj.17676 · Cited by 6
An update on trials of novel lipid-lowering drugs
Wierzbicki, A. S., Reynolds, T., & Viljoen, A. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000518 · Cited by 5
Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases
Shah, P. K. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-0993-8 · Cited by 5
Beyond Statins: Who and When to Prescribe?
Ganda, O. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1087-0 · Cited by 5
PCSK9 Inhibition could be Effective for Acute Myocardial Infarction
Gencer, B., & Mach, F. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210804091003 · Cited by 5
Self-citationIndications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk
Behr, P. E. B., Moriguchi, E. H., Castro, I., Bodanese, L. C., Dutra, Ó. P., Leães, P. E., & Filho, P. P. (2018) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20180133 · Cited by 5
Irugalbandara, A. I. (2020) · Queensland University of Technology · doi:10.5204/thesis.eprints.203805 · Cited by 5
Suswidiantoro, V., Puteri, M. U., Kato, M., Ariestanti, D. M., James, R. J., & Saputri, F. C. (2025) · Life · doi:10.3390/life15121851 · Cited by 4
“Long-term safety data and follow-up analyses from these studies have offered early hints of a possible connection between PCSK9 and dementia risk [11,22].”
Nicholls, S. J., Ray, K. K., Lincoff, A. M., Sarnes, E., Gillard, K. K., Bloedon, L., Migliaccio-Walle, K., Elsea, D., & Nissen, S. E. (2026) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00753-w · Cited by 4
Rossi, R., Nouri, A., Akman, Z., Nezhad, S. A., Damluji, A. A., & Nanna, M. G. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02329-1 · Cited by 5
Are lipid-lowering drugs harmful to cognitive performance?: A Mendelian randomization study
Han, L., Su, C., Lian, R., Han, J., Fan, X., & Gao, L. (2025) · Medicine · doi:10.1097/md.0000000000044260 · Cited by 4
Seki, T., Takiguchi, T., Akagi, Y., Ito, H., Kubota, K., Miyake, K., Okada, M., & Kawazoe, Y. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.09.004 · Cited by 4
Targeting of PCSK9 in the Management of Alzheimer's Disease: Expanding the New Potential Key Player
Alanazi, M., Al‐kuraishy, H. M., Hussain, N. R., Waheed, H. J., Al-Gareeb, A. I., Albuhadily, A. K., Waheeb, T. S., & Batiha, G. E. (2026) · Drug Development Research · doi:10.1002/ddr.70231 · Cited by 4
Armario, P., Brotons, C., Elosúa, R., de Leciñana, M. A., Castro, A., Clarà, A. B. I., Cortés, O., Rodríguez, Á. D., Herranz, M., Justo, S., et al. (2020) · PubMed Central · Cited by 4
Hyperlipidemia: effective disease management with a focus on PCSK9 inhibitors
Shaw, P. B. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88606 · Cited by 4
Gami, A., Everitt, I., Blumenthal, R. S., Newby, L. K., Virani, S. S., & Kohli, P. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.10.013 · Cited by 4
Ferreira, N. V., Bittencourt, M. S., Generoso, G., Gonçalves, N. G., Barreto, S. M., Giatti, L., Santos, R. D., Lotufo, P. A., Benseñor, I. M., & Suemoto, C. K. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119159 · Cited by 5
Targeting PCSK9 beyond the liver: evidence from experimental and clinical studies
Dalt, L. D., Baragetti, A., & Norata, G. D. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2482545 · Cited by 4
Very low LDL-cholesterol concentrations achieved: which target is next?
Hovingh, G. K., Boekholdt, S. M., & Stroes, E. S. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32292-4 · Cited by 4
The year in cardiology 2017: prevention
Nordestgaard, B. G., Cosentino, F., Landmesser, U., & Laufs, U. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx766 · Cited by 4
Management of Severe Dyslipidaemia: Role of PCSK9 Inhibitors
Nicholls, S. J. (2018) · European Cardiology Review · doi:10.15420/ecr.2018.3.2 · Cited by 4
Gil-Núñez, A., Masjuán, J., Montaner, J., Castellanos, M., Segura, T., Cardona, P., Tembl, J. I., Purroy, F. F., Arenillas, J. F., & Palacio, E. (2021) · Neurología (English Edition) · doi:10.1016/j.nrleng.2020.11.014 · Cited by 4
PCSK9 inhibitors: role in reducing cardiovascular diseases
Malyarevskaya, O. V., Муратович, Н. А., Кручинова, С. В., & Kosmacheva, E. D. (2022) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2022-3-2-32-40 · Cited by 5
Ren, Z. (2022) · Contrast Media & Molecular Imaging · doi:10.1155/2022/9871800 · Cited by 4
RetractedPCSK9 Targeting in the Management of Hypercholesterolaemia
Kosmas, C. E., Papakonstantinou, E. J., Carreño, J., Uceta, R. E., Guzman, E., & Sourlas, A. (2023) · EMJ Cardiology · doi:10.33590/emjcardiol/10303462 · Cited by 4
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4
LDL-C Targets in Secondary Prevention: How Low Should We Go?
Bayoumy, K., Gaber, M., Mani, P., Puri, R., Donnellan, E., Cho, L., Clark, D., Martin, S. S., & Elshazly, M. B. (2019) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-019-0619-8 · Cited by 4
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors
Leong, D., & Wu, P. E. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.190107 · Cited by 4
Lyall, D. M., Ward, J., Banach, M., Smith, G. D., Gill, J. M. R., Pell, J. P., Holmes, M. V., & Sattar, N. A. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/335877 · Cited by 4
Bertolotti, M., Lancellotti, G., & Mussi, C. (2023) · Journal of Gerontology and Geriatrics · doi:10.36150/2499-6564-n637 · Cited by 3
Diévart, F., Bruckert, É., Aboyans, V., Bekka, S., Boccara, F., Munoz, B. B. B., Emmerich, J., Farnier, M., Gallo, A., Lemesle, G., et al. (2024) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2024.02.004 · Cited by 3
Gil-Núñez, A., Masjuán, J., Montaner, J., Castellanos, M., Segura, T., Cardona, P., Tembl, J. I., Purroy, F. F., Arenillas, J. F., & Palacio, E. (2021) · Neurología · doi:10.1016/j.nrl.2020.11.006 · Cited by 3
Coindreau-Frías, F., Fernández-Garza, L. E., Botello-González, L., Rodríguez-Fuentes, D. E., Barrera‐Barrera, S. A., & Barrera-Saldaña, H. A. (2021) · Archivos de Neurociencias · doi:10.31157/an.v26i2.230 · Cited by 3
Seijas‐Amigo, J., Gayoso-Rey, M., Mauriz-Montero, M. J., Suárez‐Artime, P., Casas-Martínez, A., Dominguez-Guerra, M., González-Freire, L., Estany-Gestal, A., Codero-Fort, A., Rodríguez‐Mañero, M., et al. (2022) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2022.01.003 · Cited by 3
Lipid-Targeted Atherosclerotic Risk Reduction in Older Adults: A Review
Hassen, L. J., Scarfone, S. R., & Milks, M. W. (2022) · Geriatrics · doi:10.3390/geriatrics7020038 · Cited by 3
The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs
Ballantyne, C. M., & Catapano, A. L. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i1.7 · Cited by 3
FISIOPATOLOGIA E TRATAMENTOS ATUALMENTE DISPONÍVEIS PARA DISLIPIDEMIA
Almeida, A. B., Pontes, B. B., Gioia, L. N., & Rangel, V. (2023) · EPITAYA eBooks · doi:10.47879/ed.ep.2023809p32 · Cited by 3
New Biotechnological Treatments for Lipid Disorders
Valencia‐Enciso, N., & Mendivil, C. O. (2018) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.18002577 · Cited by 3
Jiang, C., Nischal, H., Sun, H., Li, L., Cao, Y., Wei, P., Chang, J., & Teng, B.-B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020640 · Cited by 3
Pharmacogenomics of Blood Lipid Regulation
Legault, M., Tardif, J., & Dubé, M. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0007 · Cited by 4
Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events
Turgeon, R. D., & Pearson, G. J. (2018) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp170707 · Cited by 5
Advances in Clinical Cardiology 2017: A Summary of Key Clinical Trials
McQuillan, C., Gray, A. P., Kearney, A., & Menown, I. B. A. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0716-y · Cited by 3
Simeone, P. G., Vadini, F., Tripaldi, R., Liani, R., Ciotti, S., Di Castelnuovo, A., Cipollone, F., & Santilli, F. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.632655 · Cited by 3
PCSK9 deficiency: A double-edged sword?
Gielen, S. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317733565 · Cited by 3
A Review of MXene Memristive Networks: Atomic‐Scale Engineering to Neuromorphic System Integration
Yang, S., Wang, J., Tan, D., Sun, N., Shi, H., Bi, S., & Jiang, C. (2025) · Advanced Materials Technologies · doi:10.1002/admt.202500685 · Cited by 2
Innovative drug discovery for cardiovascular metabolic inflammation diseases
Zhao, Y., Wang, Q., Ma, Y., Wang, J., Han, Y., & Ji, Y. H. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70131 · Cited by 2
PCSK9 Inhibitor and Potential Decreased Risk of Neoplasms, Especially in Females: A Meta-Analysis
Wei, T., Li, Z., Lin, C., Yang, Y., Tie, C., Cai, X., Lv, F., Yang, W., & Ji, L. (2025) · Pharmaceuticals · doi:10.3390/ph18081095 · Cited by 2
Kolios, N.-G., Barkas, F., Ntaios, G., & Milionis, H. J. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2675-0551 · Cited by 3
Nasini, S., Barzon, B., Tidei, S., Rossi, I., Lupo, M. G., Ferri, N., & Comai, S. (2025) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2025.107660 · Cited by 2
Zhang, L., Zhang, L., Zhao, J., Zhang, W. Y., & Zhang, H. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05424-0 · Cited by 3
Armario, P., Brotons, C., Elosúa, R., de Leciñana, M. A., Castro, A., Clarà, A. B. I., Cortés, O., Rodríguez, Á. D., Herranz, M., Justo, S., et al. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.11.004 · Cited by 2
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
Shikaleva, А. А., Maksimov, М. L., & Kiseleva, N. M. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-21-12-18 · Cited by 2
Updates on Non-Statin LDL-Lowering Therapy
Abdulla, A., Shalaby, M., Kumfa, P. N., Raja, M. W., Allencherril, J., & Sharifeh, T. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02028-3 · Cited by 4
OS TIPOS DE TRATAMENTOS ATUALMENTE DISPONÍVEIS PARA DISLIPIDEMIA E CONTROLE DOS TRIGLICERÍDEOS
Nogueira, D. R., Melo, G. C. D. C., Silva, I. D. A. C. E., Moreira, L. E. P., Pedrosa, M. D. S. B., Cardinali, M. D. P., Peron, P. L. V., & Piazzi, R. G. (2024) · EPITAYA eBooks · doi:10.47879/ed.ep.2024264p13 · Cited by 2
Green, H. J., O’Shea, O. K., Cotter, J., Philpott, H. L., & Newland, N. (2024) · Harm Reduction Journal · doi:10.1186/s12954-024-00993-0 · Cited by 2
Managed care pharmacist updates for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
Patel, J. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88608 · Cited by 2
Safety Considerations of Pharmacological Treatment
Kim, K., & Choi, S. H. (2021) · Stroke revisited · doi:10.1007/978-981-16-3923-4_17 · Cited by 2
Drugs that affect lipid metabolism
Tran, R. J. C., & Phoenix, A. (2019) · Side effects of drugs annual · doi:10.1016/bs.seda.2019.08.004 · Cited by 2
Statins for Primary Prevention in the Elderly
Nicholls, S. J., & Nelson, A. J. (2020) · JAMA · doi:10.1001/jama.2020.8390 · Cited by 2
Adverse events to PCSK-9 inhibitors: what is the current evidence?
Floyd, C., & Crook, M. A. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138746 · Cited by 2
Should We Target Global Risk or Risk Factors?
Tokgözoğlu, L. S., & Koçyiğit, D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00898-w · Cited by 2
Safety Issues Associated With the Clinical Application of PCSK9 Inhibitors: Current Findings
Wang, D., & Zhang, D. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000441 · Cited by 2
Effect of Long-Term Low Lipoproteins on Neurocognitive Function
Verbeek, R., Boekholdt, S. M., Luben, R., Stroes, E. S. G., Khaw, K., & Hovingh, G. K. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.043 · Cited by 2
New Frontier in Lipids: PCSK9 Inhibitors and Implications for the Life Insurance Industry
Tarpley, A. J. (2018) · Journal of Insurance Medicine · doi:10.17849/insm-47-4-1-6.1 · Cited by 2
Sabouret, P. F., Angoulvant, D., Pathak, A., Costa, F., Pezel, T., & Michos, E. D. (2019) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-019-0627-8 · Cited by 2
López-Santi, R., Martínez, F. A., Baranchuk, A. M., Liprandi, Á. S., Piskorz, D. L., Lorenzatti, A. J., Kaski, J. C., & VIPFARMA ISCP Investigators (2021) · European Cardiology Review · doi:10.15420/ecr.2020.42 · Cited by 2
Miao, J., Wang, J., Zhou, W., & Guo, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-46671-y · Cited by 1
Başaran, Ö. (2020) · Updates in Cardiology · doi:10.5543/ucard.2019.09719 · Cited by 2
Moon, D., Hur, S., Lee, S. R., Jeong, M. H., Cho, K. H., Kwon, O., Jeong, J., & Yoo, K. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00430-8 · Cited by 1
Antibody-Based Therapeutics for Hypercholesterolemia
Tomlinson, B., & Chan, P. (2025) · Biologics · doi:10.2147/btt.s500456 · Cited by 1
Uddin, M., Shah, A., Hemida, M. F., Afridi, M. J., Bacha, Z., Iftikhar, H., Khan, S., Saif, H., Jamal, A., Syed, A., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.012 · Cited by 1
Jing, A., Wang, J., Zhang, M., Liang, Y., Liu, J., Zhang, N., Wang, J., Li, X., Li, C., Cui, Z., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-26495-y · Cited by 1
Association between three lipid-lowering drugs and amnesia: a real-world pharmacovigilance study
Chen, J., Wu, Y., Liu, Y., Zhai, X., Xu, Y., Tang, X., Zhu, Q., Chen, Z., Li, W., Zhu, Y., et al. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05023-3 · Cited by 1
Li, Z., Li, X., Zhang, Y., Qi, J., Ji, L., Li, S., Gu, M., Liu, Y., Zhang, Y., Mei, Y., et al. (2026) · PeerJ · doi:10.7717/peerj.20668 · Cited by 1
Combination Lipid-Lowering Therapy After ACS: Should this be the New Standard of Care?
Brandts, J., & Marx, N. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02346-8 · Cited by 1
Yamamoto, T., Takahashi, Y., Takagi, S., Kitabayashi, R., Ishii, S., Sugihara, G., Oyama, J., Miyazaki, S., Goya, M., Hirakawa, A., et al. (2026) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2025.12.037 · Cited by 1
Upfront Combination or Stepwise Escalation: Personalising LDL-C Reduction in Clinical Practice
Pirillo, A., & Catapano, A. L. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01400-8 · Cited by 1
Brain, benefit, or burden? Revisiting statins and cognitive function in older adults
Liu, Y., & Kunutsor, S. K. (2026) · GeroScience · doi:10.1007/s11357-026-02259-y · Cited by 1
Zárate-Correa, L. C., García-Peña, Á. A., Kaiser, S. E., Aguilar-Salinas, C. A., Méndez-Castillo, M., Mehta, R., Valério, C. M., Moreira, R. O., Mancillas‐Adame, L. G., Canto, J. A. C., et al. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120783 · Cited by 2
Palabıyık, E. (2026) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-026-01033-8 · Cited by 1
Therapie der diabetischen Dyslipidämie
Brandts, J., & Lebherz, C. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0362-7 · Cited by 1
Guia prático para a utilização dos inibidores da PCSK9 em Portugal
Fontes‐Carvalho, R., Silva, P. M., Rodrigues, E., Araújo, F., Gavina, C., Ferreira, J., & Morais, J. (2019) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2019.05.005 · Cited by 6
Toth, P. P. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_14 · Cited by 1
Studies into the association between LDL-C lowering and cognitive function: time to forget about it?
Ibrahim, S., Reeskamp, L. F., & Hovingh, G. K. (2021) · 中国科学通报：英文版 · doi:10.1016/j.scib.2021.05.004 · Cited by 1
Estado autonómico y poder judicial
Mestre, J. B. I. (2002) · Dialnet (Universidad de la Rioja) · Cited by 1
Katzmann, J. L., Custodis, F., Schirmer, S. H., & Laufs, U. (2022) · Herz · doi:10.1007/s00059-022-05112-y · Cited by 1
Neue Optionen zur Intensivierung der lipidsenkenden Therapie
Baessler, A., & Fischer, M. (2022) · Herz · doi:10.1007/s00059-022-05111-z · Cited by 1
Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors
Seijas‐Amigo, J., Gayoso-Rey, M., Mauriz-Montero, M. J., Suárez‐Artime, P., Casas-Martínez, A., Dominguez-Guerra, M., González-Freire, L., Estany-Gestal, A., Codero-Fort, A., Rodríguez‐Mañero, M., et al. (2022) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2022.08.002 · Cited by 1
Bashir, B., Iqbal, Z., Schofield, J. D., & Soran, H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00012-7 · Cited by 1
Chen, L., Peng, H., Wang, B., Yu, W., Ding, X., Gao, M., & Yu, Y. (2023) · Medicine · doi:10.1097/md.0000000000034247 · Cited by 1
Metadata
- Authors
- Giugliano, R. P., Mach, F., Zavitz, K., Kurtz, C., Im, K., Kanevsky, E., Schneider, J., Wang, H., Keech, A., Pedersen, T. R., Sabatine, M. S., Sever, P. S., Robinson, J. G., Honarpour, N., Wasserman, S. M., & Ott, B. R.
- Affiliations
- Oslo University Hospital (NO)
- University of Iowa (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-17
- Volume
- 377
- Issue
- 7
- Pages
- 633-643
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2746224452
- Cited by
- 492
- References
- 29
- Citations by year
- 2026: 36 · 2025: 39 · 2024: 35 · 2023: 41 · 2022: 46 · 2021: 63 · 2020: 68 · 2019: 63 · 2018: 75 · 2017: 23
- FWCI
- 64.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0513-10059)
- University of California, Davis
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- evolocumab, PCSK9 inhibitors, cognitive function, executive function, spatial working memory, working memory, episodic memory, psychomotor speed, LDL cholesterol, statin therapy, non-inferiority, cognitive safety, hypercholesterolemia, Alzheimer's disease risk, dementia risk, cognitive decline
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Anticholesteremic Agents, Cognition, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Cholesterol, LDL, Male, Memory, Middle Aged, Prospective Studies, Psychological Tests, Self-Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
